Corbus Pharmaceuticals Holdings, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated May 18, 2023, details the results of the Annual Meeting of Security Holders for Corbus Pharmaceuticals Holdings, Inc. The company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol CRBP.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results and does not contain financial performance data.
Material Changes
No material financial changes or operational updates are reported in this filing. The document serves to disclose the outcome of shareholder votes held on May 18, 2023.
Guidance, Outlook, and Voting Results
Three matters were submitted to a vote of security holders:
- Election of Directors: All eight nominees (Yuval Cohen, Alan Holmer, Avery W. Catlin, Peter Salzmann, John Jenkins, Rachelle Jacques, Anne Altmeyer, and Yong Ben) were elected for a one-year term. Significant broker non-votes (1,633,476) were recorded for all director nominees.
- Ratification of Auditors: The appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, was approved with 1,806,011 votes for, 126,343 against, and 15,139 abstentions.
- Executive Compensation (Say-on-Pay): The advisory proposal to approve executive compensation was approved with 244,160 votes for, 60,487 against, and 9,370 abstentions. Broker non-votes totaled 1,633,476.
Key Facts for Investor Verification
- Verify the high volume of broker non-votes (1,633,476) on director and compensation proposals, which may indicate a significant portion of shares held in street name where brokers lacked discretionary voting power.
- Confirm the re-election of the current board composition, including CEO Yuval Cohen.
- Note the approval of EisnerAmper LLP as the auditor for the 2023 fiscal year.
- Review the definitive proxy statement for detailed executive compensation data referenced in the advisory vote.